EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade

Eric J Miller iD, Tracy L Rose, Benjamin L Maughan iD, Matthew I Milowsky iD, Mehmet A Bilen iD, Bradley C Carthon, Xin Gao, Suthee Rapisuwon, Qianqian Zhao, Menggang Yu, Neeraj Agarwal, Matthew D Galsky

Cancer · 2024

DOI: 10.1002/cncr.35179 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2024. Verfasst von Eric J Miller und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Astra-Zeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) blockade has changed the landscape of treatment for metastatic urothelial cancer, but single‐agent cytotoxic T‐lymphocyte–associated protein 4 (CTLA‐4) blockade in metastatic urothelial cancer has been underexplored. A prior phase 2 trial of tremelimumab in PD‐1/PD‐L1–blockade naive patients with metastatic urothelial cancer revealed activity comparable to that observed with PD‐1/PD‐L1 blockade raising the hypothesis that these classes of immune checkpoint inhibitors might be non‐cross‐resistant.

Methods

The current phase 2 trial treated patients with PD‐1/PD‐L1 blockade‐resistant metastatic urothelial cancer with single‐agent tremelimumab (750 mg intravenously every 28 days for up to 7 cycles). The primary end point was objective response rate.

Results

Twenty‐six patients were enrolled and 24 patients were evaluable for response. The objective response rate was 8.3%, composed of a total of two partial responses that lasted 10.9 and 24.0 months. Stable disease was observed in another 20.8% of patients, with a median duration of stable disease of 5.4 months. Diarrhea occurred in 15 patients (58%), elevated hepatic transaminases occurred in seven patients (27%), and adrenal insufficiency occurred in two patients (8%); one patient died after experiencing immune‐related hepatitis.

Conclusions

High dose CTLA‐4 blockade in patients with PD‐1/PD‐L1–resistant metastatic urothelial cancer has modest activity and is associated with treatment‐related toxicity similar to prior reports.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedB7-H1 AntigenCarcinoma, Transitional CellHumansCTLA-4 AntigenProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

CTLA‐4cancerimmunotherapymetastatictremelimumabtrialurothelial

Substanzen

Antibodies, Monoclonal, HumanizedB7-H1 AntigenCTLA-4 AntigenProgrammed Cell Death 1 ReceptortremelimumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, New York, USA.
  • Division of Oncology, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Division of Hematology and Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
  • Department of Internal Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Eric J Miller, Benjamin L Maughan, Matthew I Milowsky, Mehmet A Bilen

Förderung

  • Astra-Zeneca

Zitieren

APA

Miller, E. J., Rose, T. L., Maughan, B. L., Milowsky, M. I., Bilen, M. A., Carthon, B. C., Gao, X., Rapisuwon, S., Zhao, Q., Yu, M., Agarwal, N., & Galsky, M. D. (2024). Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade. Cancer. https://doi.org/10.1002/cncr.35179

Vancouver

Miller EJ, Rose TL, Maughan BL, Milowsky MI, Bilen MA, Carthon BC, et al. Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade. Cancer. 2024. doi:10.1002/cncr.35179

BibTeX
@article{Miller2024,
  author = {Miller, Eric J and Rose, Tracy L and Maughan, Benjamin L and Milowsky, Matthew I and Bilen, Mehmet A and Carthon, Bradley C and Gao, Xin and Rapisuwon, Suthee and Zhao, Qianqian and Yu, Menggang and Agarwal, Neeraj and Galsky, Matthew D},
  title = {Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35179}
}
Kostenlos starten →